newsfilter
← Latest News
GlobeNewswire·

Cerevel Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

Completed $599 million dual convertible debt and equity financing to advance a robust neuroscience therapeutics pipeline Initiated EMPOWER-3, a 52-week open-label extension trial of emraclidine in people with